免疫原性
信使核糖核酸
背景(考古学)
纳米医学
医学
计算生物学
生物
免疫学
免疫系统
纳米技术
遗传学
基因
古生物学
纳米颗粒
材料科学
作者
Xiangang Huang,Na Kong,Xingcai Zhang,Yihai Cao,Róbert Langer,Wei Tao
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2022-11-01
卷期号:28 (11): 2273-2287
被引量:480
标识
DOI:10.1038/s41591-022-02061-1
摘要
Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer–BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy. The COVID-19 mRNA vaccines have transformed the field of mRNA nanomedicine, but this new class of therapeutics has the potential to treat many other diseases. This Review profiles the latest advances and challenges.
科研通智能强力驱动
Strongly Powered by AbleSci AI